Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Prostate Cancer Genome Network Wins $20M from Prostate Cancer Canada, OICR

Premium

A new research project called the Canadian Prostate Cancer Genome Network plans to study the genomics of prostate cancer, the International Cancer Genome Consortium said this week.

The network, one of 37 projects conducted under the ICGC's umbrella, is funded with up to CA$15 million ($15.2 million) from Prostate Cancer Canada and CA$5 million ($5.1 million from the Ontario Institute for Cancer Research.

According to the ICGC, it will "map the genetic structure of prostate cancer and provide new information that could greatly improve the diagnosis and treatment of the disease."

The project, dubbed CPC GENE, will be led by Robert Bristow, a senior scientist at the Ontario Cancer Institute, the research arm of the University Health Network's Princess Margaret Hospital, and a genitourinary radiation oncologist at PMH.

It will involve Canadian researchers in Vancouver, Calgary, Toronto, Kingston, and Montreal, who will collaborate with research teams in the UK, France, and Germany.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.